Oxaliplatin in Combination With Capecitabine and Concurrent Radiation Therapy in Non-Small Cell Lung Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the most suitable dose of Oxaliplatin that can be safely given in combination with a low fixed dose of Capecitabine and a limited volume of radiation in patients with non-small cell lung cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase II (Treatment) Study of Oxaliplatin and Capecitabine in Advanced Head and Neck Malignancies

NCT00266279

Head or Neck Cancer

COMPLETED PHASE2

Pemetrexed &Oxaliplatin in Patients w Recurrent NSCLCa After Failure to Platinum Based Adjuvant Chem

NCT00612677

Lung Cancer

TERMINATED PHASE2

Oxaliplatin and Capecitabine in the Treatment of Relapsed/Refractory Carcinoma of Unknown Primary Site

NCT00193609

Neoplasms, Unknown Primary

COMPLETED PHASE2

Phase I Study of the Combination of Satraplatin and Abraxane in Advanced Cancers

NCT00473720

Advanced Cancers

COMPLETED PHASE1

Capecitabine and Oxaliplatin in Treating Patients With Locally Advanced, Unresectable, or Metastatic Stomach Cancer

NCT00354224

Gastric Cancer

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this study is to determine the maximum tolerated dose (MTD) and the dose limiting toxicity (DLT) of Oxaliplatin in combination with Capecitabine and radiation in subjects with non-small cell lung cancer.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Carcinoma, Non-Small Cell Lung

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Oxaliplatin

Intervention Type DRUG

Capecitabine

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* histologically proven non-small cell lung cancer
* inoperable Stage III A or B NSCLC
* must have measurable disease by RECIST criteria
* no more than one prior chemotherapy for advanced disease
* ECOG Performance Status of 0, 1, or 2
* must be able to swallow pills or have a working gastric feeding tube and no evidence of malabsorption
* negative serum beta-HCG test and under active contraception (for females of childbearing potential)
* no known allergies to any of the study drugs
* willingness to sign an informed consent

Exclusion Criteria

* women who are pregnant or breastfeeding
* ANC of less than 1500/mm3
* platelet count of less than 100,000/mm3
* estimated creatinine clearance of less than 50 cc/min (as measured by the Cockcroft-Gault equation)
* bilirubin of less than 2mg/dl
* SGPT of greater than 2x nl
* peripheral neuropathy of Grade 2 or higher
* more than one previous chemotherapy and previous radiation therapy to the chest
* a history of CHF/MI or other significant cardiac history within the last six months

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No